Rhumbline Advisers increased its position in Humana Inc. (NYSE:HUM) by 3.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 251,081 shares of the insurance provider’s stock after buying an additional 7,310 shares during the period. Rhumbline Advisers’ holdings in Humana were worth $60,415,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in HUM. Teacher Retirement System of Texas raised its position in Humana by 4.9% in the second quarter. Teacher Retirement System of Texas now owns 110,731 shares of the insurance provider’s stock worth $26,644,000 after buying an additional 5,156 shares during the period. DekaBank Deutsche Girozentrale raised its position in Humana by 75.9% in the second quarter. DekaBank Deutsche Girozentrale now owns 53,169 shares of the insurance provider’s stock worth $12,874,000 after buying an additional 22,934 shares during the period. Schwab Charles Investment Management Inc. raised its position in Humana by 25.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 649,364 shares of the insurance provider’s stock worth $156,250,000 after buying an additional 131,124 shares during the period. Canada Pension Plan Investment Board raised its position in Humana by 64.1% in the second quarter. Canada Pension Plan Investment Board now owns 230,992 shares of the insurance provider’s stock worth $55,581,000 after buying an additional 90,200 shares during the period. Finally, Global X Management Co. LLC raised its position in Humana by 8.8% in the second quarter. Global X Management Co. LLC now owns 7,708 shares of the insurance provider’s stock worth $1,855,000 after buying an additional 625 shares during the period. 99.66% of the stock is currently owned by institutional investors.

Shares of Humana Inc. (NYSE:HUM) opened at 251.67 on Friday. Humana Inc. has a one year low of $163.50 and a one year high of $255.27. The firm’s 50-day moving average price is $239.25 and its 200 day moving average price is $222.56. The stock has a market cap of $36.37 billion, a P/E ratio of 20.70 and a beta of 0.91.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. Equities research analysts expect that Humana Inc. will post $11.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Rhumbline Advisers Buys 7,310 Shares of Humana Inc. (HUM)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/rhumbline-advisers-buys-7310-shares-of-humana-inc-hum.html.

A number of research firms have weighed in on HUM. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a research note on Thursday. UBS AG restated a “neutral” rating and issued a $250.00 target price (up previously from $237.00) on shares of Humana in a research report on Wednesday. Deutsche Bank AG lifted their target price on Humana from $234.00 to $243.00 and gave the company a “hold” rating in a research report on Monday. Jefferies Group LLC restated a “hold” rating and issued a $257.00 target price on shares of Humana in a research report on Friday, August 4th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $223.00 target price (up previously from $200.00) on shares of Humana in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $243.65.

In other Humana news, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the transaction, the vice president now directly owns 8,150 shares in the company, valued at $1,890,474. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.